Apyx Medical’s Supplier Expands — But Profitability Remains Elusive

Forward-Looking Analysis

Based on the provided news content, there is no available data regarding projected revenue, net income, or EPS estimates for Apyx Medical's 2026Q2 earnings. The provided text does not contain any analyst predictions, bank upgrades, downgrades, or price targets for Apyx Medical. Consequently, no forward-looking financial metrics or analyst consensus figures can be synthesized from the given source material.

Historical Performance Review

Apyx Medical delivered mixed results in 2026Q1. The company reported revenue of $12.49 million, demonstrating top-line activity. However, profitability remained challenged with a net loss of $-2.14 million and an EPS of $-0.05. Despite the bottom-line deficit, the company maintained a gross profit of $7.92 million, indicating that while operational margins were positive, other expenses contributed to the net loss during the quarter.

Additional News

Polygon Co. announced a $4 million expansion of its medical manufacturing facility in Walkerton, targeting surgical robotics and minimally invasive devices. This expansion increases Polygon’s medical revenue share from approximately 20% to 30%. Notably, Apyx Medical is listed as one of Polygon’s existing customers, alongside Medtronic, Baxter, and Coloplast. The company already produces over 1.3 million precision medical components annually for these clients. The expansion adds 35 jobs over five years at wages roughly 9% above the South Bend-area average. This strategic shift by Polygon toward medical manufacturing may positively impact supply chain capacity and allocation for Apyx Medical, potentially supporting future production needs for minimally invasive devices.

Summary & Outlook

Apyx Medical’s financial health in 2026Q1 showed revenue stability at $12.49 million but net losses of $-2.14 million. The company maintains a gross profit of $7.92 million, suggesting core product margins are intact despite operational expenses. A key growth catalyst is the strategic expansion by supplier Polygon Co., which is increasing capacity for medical components, including those for Apyx. This supply chain strengthening supports long-term production capabilities. However, current net losses present a risk. Outlook is neutral; while supply chain improvements are positive, profitability recovery remains the critical factor for future success.